Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Pedvaxhib, Vaxelis
Generic Name
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DrugBank Accession Number
DB10342
Background

Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen is a vaccine containing outer membrane antigen extracted from Haemophilus influenzae.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Anakinra.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
PedvaxHIBInjection, suspension7.5 ug/0.5mLIntramuscularMerck Sharp & Dohme Corp.1989-12-20Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ComvaxHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (7.5 ug/0.5mL) + Hepatitis B virus subtype ADW HBSAG surface protein antigen (5 ug/0.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Limited1996-10-022016-08-19US flag
HEXAXIM 0.5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 1 ADETHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (12 µg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 µg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 µg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
HEXAXIM 0.5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 10 ADETHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (12 µg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 µg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 µg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
HEXAXIM 0.5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (12 µg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 µg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 µg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
HEXAXIM 0.5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 10 ADETHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (12 µg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 µg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 µg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
Infanrix HexaHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
LUY6P8763W
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910521
RxNav
798444

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionHepatitis A Virus1
4Not Yet RecruitingPreventionHaemophilus Influenzae Type B Infection1
4RecruitingPreventionDiphtheria1
3Active Not RecruitingTreatmentPneumococcal Infection1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases2
3CompletedPreventionBacterial Infections / Virus Diseases2
3CompletedPreventionHaemophilus Influenzae Serotype b (Hib) / Neisseria Meningitidis3
3CompletedPreventionHaemophilus Influenzae Serotype b (Hib) / Viral Hepatitis B1
3CompletedPreventionMeasles / Mumps / Rubella / Varicella1
2CompletedPreventionHaemophilus Influenzae Serotype b (Hib) / Neisseria Meningitidis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
Injection, solutionIntramuscular
InjectionIntramuscular
InjectionIntramuscular
Injection, powder, for suspensionIntramuscular
SuspensionIntramuscular
Injection, suspensionIntramuscular7.5 ug/0.5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:03 / Updated at June 12, 2020 16:53